Fig. 4: Ibrutinib sensitizes CRC cells to the ferroptosis induced by RSL3 or Erastin. | Cell Death & Disease

Fig. 4: Ibrutinib sensitizes CRC cells to the ferroptosis induced by RSL3 or Erastin.

From: RETRACTED ARTICLE: Ibrutinib facilitates the sensitivity of colorectal cancer cells to ferroptosis through BTK/NRF2 pathway

Fig. 4

A The viability and B proliferation of HT-29 and Caco-2 cells that were treated with Ibrutinib, RSL3, Erastin, Ibrutinib/RSL3 or Ibrutinib/Erastin detected by the CCK-8 assay and the colony formation assay. The C MDA and D GSH levels in HT-29 and Caco-2 cells that were treated with Ibrutinib, RSL3, Erastin, Ibrutinib/RSL3, or Ibrutinib/Erastin detected by the commercial kits. E The representative immunofluorescent staining images of Nrf2 in HT-29 and Caco-2 cells that were treated with Ibrutinib, RSL3, Erastin, Ibrutinib/RSL3, or Ibrutinib/Erastin. Scale bar = 25 μm. F The Nrf2, GPX4, SOD1, and CAT expressions in HT-29 and Caco-2 cells that were treated with Ibrutinib, RSL3, Erastin, Ibrutinib/RSL3, or Ibrutinib/Erastin detected by Western blot. All experiments were carried out at least three times, n = 3, *P < 0.05, **P < 0.01 and ***P < 0.001.

Back to article page